Four cases are reported in which respiratory arrest occurred coincident with the intravenous administration of large doses of trimethaphan camsylate (Arfonad) to control hypertension. The mechanism of the respiratory depression is unknown, but it may have been related to a direct effect of trimethaphan on the respiratory center or to a curare-like effect of the drug. Close monitoring of ventilatory capacity should be maintained in all patients treated with trimethaphan.
(Arch Intern Med 136:816-818, 1976)
Dale RC, Schroeder ET. Respiratory Paralysis During Treatment of Hypertension With Trimethaphan Camsylate. Arch Intern Med. 1976;136(7):816–818. doi:10.1001/archinte.1976.03630070060018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: